H.I.G. BioHealth Partners

The specific leadership team for H.I.G. BioHealth Partners is not publicly named. The broader H.I.G. Capital was founded by Sami Mnaymneh and Tony Tamer, but the BioHealth vertical operates as a distinct strategy within the firm. Investment decisions likely involve the strategy's managing directors and deal partners, though no public roster exists.

It operates as a dedicated investment vertical focusing on healthcare and life sciences growth equity, part of H.I.G. Capital's multi-strategy structure. The parent firm manages over $60 billion across buyout, credit, real estate, and growth equity. BioHealth is the firm's healthcare growth platform, separate from H.I.G.'s general growth equity or buyout strategies.

The firm focuses on growth-stage investments, typically in companies with clinical- or commercial-stage products. It avoids early-stage venture deals and incubation. Public filings indicate investments in publicly traded biotech firms, suggesting a later-stage posture including PIPE transactions and follow-on offerings.

The strategy appears to avoid early-stage drug discovery, preclinical assets, and medical devices without regulatory clearance. Healthcare services and digital health may be included, but the primary focus remains on therapeutics and life sciences tools. No explicit avoidance list is published.

The firm makes direct equity investments in healthcare and life sciences companies. It does not operate as a fund-of-funds or commit capital to external managers. Its investments are direct positions, primarily minority stakes, sourced through H.I.G. Capital's network and deal team.